Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity

Core Insights - Ascletis Pharma Inc. announced promising preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate, in combination with ASC31, a dual-targeting peptide agonist for GLP-1R and GIPR [2][6] Group 1: Drug Candidates - ASC47 is an adipose-targeted, once-monthly subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, developed in-house at Ascletis, which shows high drug concentrations in adipose tissue [4] - ASC31 is a novel peptide agonist targeting both GLP-1R and GIPR, demonstrating a favorable pharmacokinetic profile and promising efficacy in diet-induced obese (DIO) mice [3][5] Group 2: Efficacy Results - In a DIO mouse model, the combination of a low dose of ASC47 (9 mg/kg, SQ) with ASC31 (3 nmol/kg, SQ) resulted in a 44.8% reduction in body weight after 14 days, compared to a 38.1% reduction with ASC47 combined with tirzepatide [1][5] - The combination of ASC47 with ASC31 was found to be 17.6% more effective than the combination with tirzepatide, with statistical significance (p=0.02) [5] Group 3: Company Overview - Ascletis Pharma Inc. is focused on developing and commercializing potential best-in-class and first-in-class therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [7]